Jordi Remon, Thoracic Oncologist at CIOCC Barcelona, shared a post on X:
“Selective TKIs are the mainstay treatment for most fusions. Current challenges: availability of multiple competitive options, how to sequence and access. In absence of predictive biomarkers: CNS activity and toxicity are relevant. Role of upfront CT + TKI in fusion+ NSCLC remains uk.”
More posts featuring Jordi Remon on OncoDaily.
